Avicanna Reveals New CFO Appointment

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Sep 12 2025

0mins

Source: Newsfilter

Leadership Change: Avicanna Inc. has appointed Nick Hilborn as Interim Chief Financial Officer, succeeding Phillip Cardella, who will transition to a consulting role effective September 15, 2025.
Company Overview: Avicanna is a biopharmaceutical company focused on developing and commercializing plant-derived cannabinoid-based products, with a diverse range of proprietary products and a strong emphasis on research and development.
Product Offerings: The company offers a variety of cannabinoid-based products through its RHO Phyto™ brand and operates a medical cannabis care platform, MyMedi.ca, aimed at enhancing patient support and education.
Pharmaceutical Pipeline: Avicanna is developing a pipeline of proprietary cannabinoid-based candidates targeting unmet medical needs in areas such as dermatology, chronic pain, and neurological disorders, supported by its subsidiary's supply of active pharmaceutical ingredients.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.